These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 15648082

  • 1. Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years.
    Postma R, de Vries SH, Roobol MJ, Wildhagen MF, Schröder FH, van der Kwast TH.
    Cancer; 2005 Feb 15; 103(4):708-16. PubMed ID: 15648082
    [Abstract] [Full Text] [Related]

  • 2. Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years.
    Postma R, Roobol M, Schröder FH, van der Kwast TH.
    Cancer; 2004 Mar 01; 100(5):968-75. PubMed ID: 14983492
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan.
    Yokomizo A, Murai M, Baba S, Ogawa O, Tsukamoto T, Niwakawa M, Tobisu K, Kinukawa N, Naito S.
    BJU Int; 2006 Sep 01; 98(3):549-53. PubMed ID: 16925752
    [Abstract] [Full Text] [Related]

  • 5. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C, Kestin LL, Weed DW, Krauss D, Vicini FA, Martinez AA.
    Int J Radiat Oncol Biol Phys; 2005 Mar 01; 61(3):714-24. PubMed ID: 15708249
    [Abstract] [Full Text] [Related]

  • 6. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening.
    Postma R, Schröder FH, van Leenders GJ, Hoedemaeker RF, Vis AN, Roobol MJ, van der Kwast TH.
    Eur Urol; 2007 Jul 01; 52(1):89-97. PubMed ID: 17257742
    [Abstract] [Full Text] [Related]

  • 7. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma.
    Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG.
    Cancer; 2004 Apr 01; 100(7):1397-405. PubMed ID: 15042673
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
    Ito K, Raaijmakers R, Roobol M, Wildhagen M, Yamanaka H, Schröder FH.
    Cancer; 2005 Jan 15; 103(2):242-50. PubMed ID: 15578715
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysis.
    Zhu H, Roehl KA, Antenor JA, Catalona WJ.
    Urology; 2005 Sep 15; 66(3):547-51. PubMed ID: 16140075
    [Abstract] [Full Text] [Related]

  • 14. The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable.
    Zackrisson B, Aus G, Bergdahl S, Lilja H, Lodding P, Pihl CG, Hugosson J.
    J Urol; 2004 Apr 15; 171(4):1500-3. PubMed ID: 15017207
    [Abstract] [Full Text] [Related]

  • 15. Primary treatment choices for men with clinically localized prostate carcinoma detected by screening.
    Yan Y, Carvalhal GF, Catalona WJ, Young JD.
    Cancer; 2000 Mar 01; 88(5):1122-30. PubMed ID: 10699903
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
    Sengupta S, Blute ML, Bagniewski SM, Inman B, Leibovich BC, Slezak JM, Myers RP, Zincke H.
    BJU Int; 2008 Jan 01; 101(2):170-4. PubMed ID: 18173824
    [Abstract] [Full Text] [Related]

  • 18. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience.
    Soloway MS, Soloway CT, Williams S, Ayyathurai R, Kava B, Manoharan M.
    BJU Int; 2008 Jan 01; 101(2):165-9. PubMed ID: 17850361
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.